Volatile Organic Compounds in Exhaled Breath, Blood, and Urine Detected in Patients with Thyroid Carcinoma Using Gas Chromatography-Ion Mobility Spectrometry- A Pilot Study.

Blood Exhaled Breath GC-IMS Thyroid Carcinoma Urine VOCs Volatile Organic Compounds

Journal

Journal of breath research
ISSN: 1752-7163
Titre abrégé: J Breath Res
Pays: England
ID NLM: 101463871

Informations de publication

Date de publication:
22 Oct 2024
Historique:
medline: 23 10 2024
pubmed: 23 10 2024
entrez: 22 10 2024
Statut: aheadofprint

Résumé

Background
Distinguishing between malignant and benign thyroid nodules remains a significant challenge for clinicians and researchers globally. The use of volatile organic compounds (VOCs) has emerged as a novel approach in cancer diagnosis. This prospective pilot study aims to identify VOCs in exhaled breath, blood, and urine that can differentiate benign from malignant thyroid nodules using gas chromatography-ion mobility spectrometry (GC-IMS).
Methods
Patients with thyroid nodules scheduled for surgery were enrolled at the Maastricht University Medical Center (MUMC+). Breath samples were analyzed using a BreathSpec GC-IMS machine (G.A.S. Dortmund, Germany), specifically designed for breath analysis. All blood and urine samples were analyzed with a separate GC-IMS device, the FlavourSpec® (G.A.S., Dortmund, Germany).
Results 
In this proof-of-concept study, 70 patients undergoing thyroid surgery at MUMC+ were consecutively included. Of these patients, 29 were confirmed to have thyroid cancer after surgical resection. The overall analysis did not reveal statistically significant differences in VOCs in breath, urine and blood, between patients with benign and malignant thyroid cancer. 
Conclusion
This proof-of-concept study demonstrated that GC-IMS was unable to adequately distinguish between the VOC profiles of malignant and benign thyroid nodules. However, this study had a small sample size and future larger studies are needed to investigate the potential of using VOCs to distinguish between benign and malignant thyroid nodules. Furthermore, future research should focus on investigating potential confounders that affect patient VOC profiles.
(NCT04883294)&#xD.

Identifiants

pubmed: 39437815
doi: 10.1088/1752-7163/ad89ef
doi:

Banques de données

ClinicalTrials.gov
['NCT04883294']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Creative Commons Attribution license.

Auteurs

Zaid Al-Difaie (Z)

Surgery, Maastricht University Faculty of Health Medicine and Life Sciences, Universiteitssingel 50, Maastricht, Limburg, 6200 MD, NETHERLANDS.

Max Scheepers (M)

Surgery, Maastricht University Faculty of Health Medicine and Life Sciences, Universiteitssingel 50, Maastricht, Limburg, 6200 MD, NETHERLANDS.

Sanne Engelen (S)

Surgery, Maastricht University Medical Centre+, P. Debyelaan 25, Maastricht, Limburg, 6229 HX, NETHERLANDS.

Tim Lubbers (T)

Surgery, Maastricht University Medical Centre+, PO Box 5800, Maastricht, Limburg, 6202AZ, NETHERLANDS.

Bas Havekes (B)

Department of Internal Medicine, Division of Endocrinology, Maastricht University Medical Centre+, P. Debyelaan 25, Maastricht, Limburg, 6229 HX, NETHERLANDS.

Nicole Bouvy (N)

Surgery, Maastricht University Medical Centre+, PO Box 5800, Maastricht, Limburg, 6202AZ, NETHERLANDS.

Classifications MeSH